Edgar Filing: DUSA PHARMACEUTICALS INC - Form 3

DUSA PHARMACEUTICALS INC

Form 3

September 19, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Todisco Michael

(Last) (First)

Statement

(Month/Day/Year)

09/19/2006

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

DUSA PHARMACEUTICALS INC [DUSA]

(Middle)

C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE

(Street)

4. Relationship of Reporting Person(s) to Issuer

Filed(Month/Day/Year)

(Check all applicable)

Director _X__ Officer

10% Owner

Other (give title below) (specify below) Vice President, Controller

6. Individual or Joint/Group

5. If Amendment, Date Original

Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

WILMINGTON, MAÂ 01887

(City) (State)

1. Title of Security (Instr. 4)

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Form: Direct (D)

or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

Date

Exercisable

3. Title and Amount of Securities Underlying Derivative Security

4.

5. Conversion or Exercise

Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership (Instr. 5)

(Instr. 4)

Expiration

Title Amount or Number of Derivative Security

Price of

Security: Direct (D)

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Employee Stock Option	(1)	05/01/2015	Common Stock	20,000	\$ 10.37	D	Â
Employee Stock Option	(2)	03/26/2016	Common Stock	4,000	\$ 6.75	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships					
.k 9	Director	10% Owner	Officer	Other		
Todisco Michael C/O DUSA PHARMACEUTICALS, INC. 25 UPTON DRIVE WILMINGTON Â MAÂ 01887	Â	Â	Vice President, Controller	Â		

Signatures

/s/ Michael
Todisco

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option granted on May 2, 2005, options vest at the rate of one-quarter of the total granted on each of the first, second, third and fourth anniversaries of the date of grant.
- Option granted on March 27, 2006, options vest at the rate of one-quarter of the total granted on each of the first, second, third and fourth anniversaries of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2